Edward Tenthoff
Stock Analyst at Piper Sandler
(2.44)
# 2,486
Out of 5,067 analysts
184
Total ratings
43.5%
Success rate
-0.13%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Edward Tenthoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRNA Moderna | Reiterates: Overweight | $69 → $63 | $24.15 | +160.87% | 13 | Nov 21, 2025 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Overweight | $45 → $70 | $44.26 | +58.16% | 12 | Nov 19, 2025 | |
| INO Inovio Pharmaceuticals | Reiterates: Overweight | $5 → $6 | $1.81 | +231.49% | 2 | Nov 14, 2025 | |
| ALNY Alnylam Pharmaceuticals | Reiterates: Overweight | $449 → $489 | $434.23 | +12.61% | 15 | Oct 31, 2025 | |
| FULC Fulcrum Therapeutics | Reiterates: Overweight | $13 → $16 | $11.74 | +36.29% | 5 | Oct 30, 2025 | |
| KPTI Karyopharm Therapeutics | Reiterates: Overweight | $15 → $12 | $5.56 | +115.83% | 1 | Oct 9, 2025 | |
| CAMP Camp4 Therapeutics | Maintains: Overweight | $18 → $12 | $3.33 | +260.36% | 2 | Sep 15, 2025 | |
| NXTC NextCure | Maintains: Overweight | $36 → $15 | $14.11 | +6.31% | 5 | Jul 15, 2025 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Overweight | $105 | $51.25 | +104.88% | 7 | Jun 27, 2025 | |
| STRO Sutro Biopharma | Upgrades: Overweight | $2 | $0.88 | +128.57% | 7 | Jun 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $7 | $1.01 | +593.07% | 1 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $24 → $14 | $11.77 | +18.95% | 7 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $2 | $0.52 | +284.62% | 8 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $48 | $21.67 | +121.50% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $15 → $24 | $15.62 | +53.65% | 5 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $78 | $27.15 | +187.29% | 4 | Dec 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 → $30 | $16.74 | +79.21% | 4 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $65 | $4.17 | +1,458.75% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $4.64 | +654.31% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $20 | $1.30 | +1,438.46% | 3 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.30 | +130.77% | 6 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $3 | $0.59 | +408.30% | 4 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $15.76 | +1.52% | 3 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $4 → $6 | $1.08 | +455.56% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $2.37 | +110.97% | 4 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $56 | $65.59 | -14.62% | 4 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $224 → $248 | $29.07 | +753.11% | 5 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $3.80 | +2,268.42% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $180 | $16.91 | +964.46% | 3 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $44 | $15.77 | +179.01% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $76 → $37 | $6.74 | +448.96% | 2 | May 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $2,246,640 → $651,200 | $1.18 | +55,186,340.68% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $250 → $354 | $907.42 | -60.99% | 4 | Nov 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $135 | $1.63 | +8,182.21% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $261 → $323 | $424.00 | -23.82% | 6 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $33 → $36 | $42.25 | -14.79% | 2 | Feb 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $25 | $1.13 | +2,112.39% | 2 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $150 | $0.79 | +18,887.34% | 1 | Jan 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $13,800 | $2.74 | +503,549.64% | 1 | Dec 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $761.45 | - | 11 | Feb 13, 2017 |
Moderna
Nov 21, 2025
Reiterates: Overweight
Price Target: $69 → $63
Current: $24.15
Upside: +160.87%
Arrowhead Pharmaceuticals
Nov 19, 2025
Maintains: Overweight
Price Target: $45 → $70
Current: $44.26
Upside: +58.16%
Inovio Pharmaceuticals
Nov 14, 2025
Reiterates: Overweight
Price Target: $5 → $6
Current: $1.81
Upside: +231.49%
Alnylam Pharmaceuticals
Oct 31, 2025
Reiterates: Overweight
Price Target: $449 → $489
Current: $434.23
Upside: +12.61%
Fulcrum Therapeutics
Oct 30, 2025
Reiterates: Overweight
Price Target: $13 → $16
Current: $11.74
Upside: +36.29%
Karyopharm Therapeutics
Oct 9, 2025
Reiterates: Overweight
Price Target: $15 → $12
Current: $5.56
Upside: +115.83%
Camp4 Therapeutics
Sep 15, 2025
Maintains: Overweight
Price Target: $18 → $12
Current: $3.33
Upside: +260.36%
NextCure
Jul 15, 2025
Maintains: Overweight
Price Target: $36 → $15
Current: $14.11
Upside: +6.31%
CRISPR Therapeutics AG
Jun 27, 2025
Reiterates: Overweight
Price Target: $105
Current: $51.25
Upside: +104.88%
Sutro Biopharma
Jun 16, 2025
Upgrades: Overweight
Price Target: $2
Current: $0.88
Upside: +128.57%
Jun 3, 2025
Assumes: Overweight
Price Target: $7
Current: $1.01
Upside: +593.07%
May 2, 2025
Reiterates: Overweight
Price Target: $24 → $14
Current: $11.77
Upside: +18.95%
Mar 20, 2025
Maintains: Overweight
Price Target: $4 → $2
Current: $0.52
Upside: +284.62%
Feb 28, 2025
Maintains: Overweight
Price Target: $53 → $48
Current: $21.67
Upside: +121.50%
Feb 7, 2025
Reiterates: Overweight
Price Target: $15 → $24
Current: $15.62
Upside: +53.65%
Dec 30, 2024
Reiterates: Overweight
Price Target: $78
Current: $27.15
Upside: +187.29%
Dec 2, 2024
Upgrades: Overweight
Price Target: $20 → $30
Current: $16.74
Upside: +79.21%
Nov 13, 2024
Maintains: Overweight
Price Target: $104 → $65
Current: $4.17
Upside: +1,458.75%
Oct 21, 2024
Initiates: Overweight
Price Target: $35
Current: $4.64
Upside: +654.31%
Sep 20, 2024
Reiterates: Overweight
Price Target: $20
Current: $1.30
Upside: +1,438.46%
Sep 17, 2024
Reiterates: Overweight
Price Target: $3
Current: $1.30
Upside: +130.77%
Jul 26, 2024
Maintains: Overweight
Price Target: $8 → $3
Current: $0.59
Upside: +408.30%
Jun 28, 2024
Reiterates: Overweight
Price Target: $16
Current: $15.76
Upside: +1.52%
Jun 17, 2024
Upgrades: Overweight
Price Target: $4 → $6
Current: $1.08
Upside: +455.56%
Mar 5, 2024
Maintains: Overweight
Price Target: $6 → $5
Current: $2.37
Upside: +110.97%
Feb 27, 2024
Maintains: Overweight
Price Target: $39 → $56
Current: $65.59
Upside: -14.62%
Aug 14, 2023
Maintains: Overweight
Price Target: $224 → $248
Current: $29.07
Upside: +753.11%
Dec 12, 2022
Initiates: Overweight
Price Target: $90
Current: $3.80
Upside: +2,268.42%
Sep 7, 2022
Maintains: Overweight
Price Target: $140 → $180
Current: $16.91
Upside: +964.46%
Aug 25, 2022
Maintains: Overweight
Price Target: $37 → $44
Current: $15.77
Upside: +179.01%
May 23, 2022
Maintains: Overweight
Price Target: $76 → $37
Current: $6.74
Upside: +448.96%
May 13, 2022
Maintains: Overweight
Price Target: $2,246,640 → $651,200
Current: $1.18
Upside: +55,186,340.68%
Nov 29, 2021
Upgrades: Overweight
Price Target: $250 → $354
Current: $907.42
Upside: -60.99%
Sep 20, 2021
Maintains: Overweight
Price Target: $105 → $135
Current: $1.63
Upside: +8,182.21%
Jul 30, 2021
Maintains: Overweight
Price Target: $261 → $323
Current: $424.00
Upside: -23.82%
Feb 16, 2021
Maintains: Overweight
Price Target: $33 → $36
Current: $42.25
Upside: -14.79%
May 12, 2020
Downgrades: Neutral
Price Target: $50 → $25
Current: $1.13
Upside: +2,112.39%
Jan 27, 2020
Initiates: Overweight
Price Target: $150
Current: $0.79
Upside: +18,887.34%
Dec 11, 2017
Initiates: Overweight
Price Target: $13,800
Current: $2.74
Upside: +503,549.64%
Feb 13, 2017
Upgrades: Overweight
Price Target: n/a
Current: $761.45
Upside: -